| Code | CSB-RA004843MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to mogamulizumab, designed to specifically bind to CC chemokine receptor 4 (CCR4). CCR4 is a G protein-coupled receptor expressed on the surface of T helper 2 (Th2) cells, regulatory T cells (Tregs), and certain subsets of T lymphocytes. This receptor plays a critical role in immune cell trafficking and homing by mediating responses to chemokines CCL17 and CCL22. CCR4 is particularly significant in cancer research, as it is highly expressed on malignant T cells in adult T-cell leukemia/lymphoma (ATLL) and cutaneous T-cell lymphoma (CTCL), as well as on tumor-infiltrating regulatory T cells in various solid tumors.
Mogamulizumab, the reference antibody, is a defucosylated humanized IgG1 kappa monoclonal antibody that exhibits enhanced antibody-dependent cellular cytotoxicity (ADCC) against CCR4-expressing cells. This biosimilar antibody serves as a valuable research tool for investigating CCR4-mediated immune regulation, tumor microenvironment dynamics, and mechanisms of T-cell-mediated malignancies. It enables researchers to explore therapeutic strategies targeting CCR4 in hematological cancers and immune-related disorders.
There are currently no reviews for this product.